Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6226662 | 1.00 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL5559301 | 0.98 | ALDH1A1 (0.37) | SLC6A3SLC6A2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL5559307 | 0.98 | ALDH1A1 (0.37) | SLC6A3SLC6A2ALDH1A1LMNATSHR | |
| SCHEMBL3601118 | 0.93 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL4955381 | 0.80 | SLC6A3 (0.33) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL23603002 | 0.79 | — | — | |
| SCHEMBL15818137 | 0.79 | — | — | |
| SCHEMBL15166346 | 0.79 | — | — | |
| SCHEMBL4838694 | 0.79 | — | — | |
| SCHEMBL6111365 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040198722-A1 | Collections of compounds | SPIROGEN LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-6747144-B1 | TREATING NEOPLASTIC DISEASES, ALZHEIMER'S DISEASE, BACTERIAL INFECTIONS, PARASITIC INFECTIONS OR VIRAL INFECTIONS | SPIROGEN LIMITED (GB) | 2004-06-08 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-1107970-A2 | COLLECTIONS OF COMPOUNDS | Spirogen Limited (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012509-A2 | COLLECTIONS OF COMPOUNDS | SPIROGEN LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
| US-5621133-A | PREPARING A 1-(3,4-DIALKOXYPHENYL),3-HYDROXYALKANE(C6-C12) BY EPOXIDIZING A HALO DERIVATIVE WITH A BASE FOLLOWED BY DECYCLICIZING WITH AN ORGANOMETALLIC COMPOUND IN A SOLVENT; NAPHTHYLENES, ISOCHROMENES AND ISOTHIOCHROMENES | DENINNO MICHAEL P (US) | 1997-04-15 | — | — | US | disclosed |
| US-5591884-A | PROTECTED HYDROXYALKYLCATECHOL INTERMEDIATES | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996038435-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | SLC6A3 832/4885SLC6A2 714/4885SLC6A4 376/4885 |
| US-20040198722-A1 | Collections of compounds | CBR3, H1-3, H1-0 | SLC6A3 635/4885SLC6A2 696/4885SLC6A4 2056/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | SLC6A3 985/4885SLC6A2 786/4885SLC6A4 339/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | SLC6A3 631/4885SLC6A2 664/4885SLC6A4 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.